Effect of Exenatide therapy in type 2diabetes with nonalcoholic fatty liver disease
10.19405/j.cnki.issn1000-1492.2017.04.018
- VernacularTitle:艾塞那肽治疗2型糖尿病合并非酒精性脂肪性肝病患者的疗效观察
- Author:
Yueshuang HU
;
Xing ZHONG
;
Tianrong PAN
- Keywords:
exenatide;
metformin;
type 2 diabetes;
nonalcoholic fatty liver disease;
therapeutic effect
- From:
Acta Universitatis Medicinalis Anhui
2017;52(4):546-549
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the therapeutic effect of exenatide combined with metformin therapy in type 2 diabetes with nonalcoholic fatty liver disease.Methods 50 patients with type 2 diabetes and nonalcoholic fatty liver disease were randomly divided into experimental group and control group with 25 cases in each.The control group were treated with metformin, the experimental group were treated with exenatide on the basis of metformin.Before treatment and at the end of 12-week treatment, patients height, weight, body mass index(BMI), waistline(WC), glycated hemoglobin(HbA1c), fasting blood glucose(FBG),fasting C-peptide(FCP), triglyceride(TG), cholesterol(TCH), high density lipoprotein(HDL), low density lipoprotein(LDL),systolic pressure(SBP), diastolic pressure(DBP), alanine aminotransferase(ALT), superoxide dismutase(SOD), liver lipid contents(LFC) were detected.Results Baseline data were not significantly different between the two groups.Compared to baseline, WC, HbA1c, FBG and LFC in experimental group and control group were obviously improved after treatment(P<0.05), and the experimental group improved more significantly than control group(P<0.05).Conclusion Exenatide combined with metformin has an obvious therapeutic effect on BMI, WC, HbA1c, FBG, FCP, SBP, TG, TCH, HDL, LDL, LFC than mere metformin treatment in treatment of type 2 diabetes with nonalcoholic fatty liver disease.
